Skip to content
2000
Volume 22, Issue 18
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

In a review [1] published in this journal in 2014 we updated the role of statin treatment in patients with type 2 diabetes mellitus (T2DM). This is an important topic because the prevalence of T2DM is increasing and this disease is associated with a high risk of cardiovascular disease (CVD) as well as microvascular complications [1]. The relationship between T2DM and statins is further complicated since these drugs can cause new onset diabetes (NOD) although there is an overall benefit in terms of preventing vascular events [1, 2]. The cost implications of T2DM in terms of quality of life as well as providing healthcare are obvious. This is a brief update of our earlier review [1] based on recently published data.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612822666160125114626
2016-05-01
2025-01-10
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612822666160125114626
Loading

  • Article Type:
    Research Article
Keyword(s): cancer; diabetes mellitus; ezetimibe; IMPROVE-IT; new onset diabetes; statins
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test